|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,217.67 MXN | +0.63% |
|
+0.63% | -0.21% |
| Jul. 03 | Trial for Ebola treatment starts in DR Congo | RE |
| Jul. 02 | Trial for Bundibugyo Ebola treatment starts in DRC, WHO says | RE |
| Market Cap | 163B 2,848B 142B 131B 122B 231B 15,518B 235B 1,572B 611B 7,628B 612B 599B 26,285B | P/E 2026 * |
-46.9x | P/E 2027 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise Value | 173B 3,016B 151B 139B 129B 245B 16,429B 249B 1,664B 647B 8,076B 648B 634B 27,829B | EV / Sales 2026 * |
5.66x | EV / Sales 2027 * | 5.03x |
| Free-Float |
99.88% | Yield 2026 * |
2.47% | Yield 2027 * | 2.53% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +0.63% | ||
| 1 week | +0.63% | ||
| Current month | +0.63% | ||
| 1 month | -0.46% | ||
| 3 months | -12.26% | ||
| 6 months | -0.21% | ||
| Current year | -0.21% |
| 1 week | 2,217.67 |  | 2,217.67 |
| 1 month | 2,116 | | 2,263 |
| Current year | 2,116 | | 2,618.71 |
| 1 year | 2,025.32 | | 2,618.71 |
| 3 years | 1,046.71 | | 2,618.71 |
| 5 years | 1,046.71 | | 2,618.71 |
| 10 years | 1,046.71 | | 2,618.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 2019-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 2019-10-31 |
Keeley Wettan
CMP | Compliance Officer | - | 2025-12-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 2016-08-18 |
| Director/Board Member | 73 | 2017-12-31 | |
Harish Manwani
BRD | Director/Board Member | 72 | 2018-05-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.63% | +0.63% | - | - | 163B | |
| +1.86% | +0.48% | +55.50% | +163.08% | 1,082B | |
| +3.57% | +3.29% | +68.60% | +61.03% | 633B | |
| +3.99% | +3.05% | +37.93% | +93.37% | 461B | |
| +3.86% | +1.64% | +32.57% | +24.89% | 339B | |
| -0.56% | +0.96% | +41.67% | +39.35% | 301B | |
| -0.08% | +1.30% | +32.15% | +44.48% | 292B | |
| -1.54% | +2.81% | -25.35% | -39.61% | 225B | |
| +3.55% | +4.41% | +25.45% | +66.28% | 202B | |
| +1.84% | +0.12% | -4.18% | -33.64% | 139B | |
| Average | +1.71% | +4.51% | +29.37% | +46.58% | 408.37B | |
| Weighted average by Cap. | +2.07% | +5.57% | +41.59% | +79.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.46B 532B 26.63B 24.47B 22.81B 43.27B 2,901B 43.93B 294B 114B 1,426B 114B 112B 4,913B | 32.36B 566B 28.29B 26B 24.23B 45.96B 3,081B 46.66B 312B 121B 1,514B 121B 119B 5,219B |
| Net income | -3.37B -58.95B -2.95B -2.71B -2.53B -4.79B -321B -4.86B -32.53B -12.65B -158B -12.66B -12.39B -544B | 9.55B 167B 8.35B 7.67B 7.15B 13.56B 909B 13.77B 92.09B 35.8B 447B 35.84B 35.07B 1,540B |
| Net Debt | 9.57B 167B 8.36B 7.69B 7.17B 13.59B 911B 13.8B 92.28B 35.88B 448B 35.92B 35.14B 1,543B | -96.43M -1.69B -84.3M -77.47M -72.21M -137M -9.18B -139M -930M -362M -4.51B -362M -354M -15.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-01 | MX$2,217.67 | +0.63% | 1,801 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD * Stock
Select your edition
All financial news and data tailored to specific country editions
